To the full analysis
Buyback calculator for Gan & Lee Pharmaceuticals.
Gan & Lee Pharmaceuticals. stock: key metrics
603087.SSGan & Lee Pharmaceuticals. had an operating margin of 18.8% and a return on invested capital (ROIC) of 8.5% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2013 | 90.3% | 33.8% | 29.6% |
| 2014 | 91.0% | 37.5% | 32.9% |
| 2015 | 91.0% | 42.8% | 36.7% |
| 2016 | 90.6% | 50.8% | 43.4% |
| 2017 | 91.3% | 53.6% | 45.6% |
| 2018 | 92.2% | 46.7% | 39.1% |
| 2019 | 91.8% | 48.3% | 40.3% |
| 2020 | 90.8% | 43.2% | 36.6% |
| 2021 | 88.9% | 47.0% | 40.2% |
| 2022 | 74.1% | −33.2% | −25.7% |
| 2023 | 72.2% | 12.1% | 13.0% |
| 2024 | 74.5% | 20.7% | 20.2% |
| 2025 | 72.7% | 18.8% | 28.3% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2013 | 27.9% | 39.3% | 24.6% |
| 2014 | 29.4% | 45.3% | 25.4% |
| 2015 | 30.1% | 39.2% | 24.7% |
| 2016 | 34.1% | 47.6% | 29.6% |
| 2017 | 32.4% | 50.3% | 28.9% |
| 2018 | 21.9% | 29.9% | 19.9% |
| 2019 | 21.3% | 30.4% | 19.4% |
| 2020 | 13.8% | 26.6% | 12.9% |
| 2021 | 14.3% | 27.5% | 13.4% |
| 2022 | −4.6% | −8.7% | −4.1% |
| 2023 | 3.2% | 5.7% | 2.9% |
| 2024 | 5.6% | 8.5% | 5.1% |
| 2025 | 9.8% | 8.5% | 9.1% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 24 Jan 2025)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.